Role of Cisplatin as Inhibitor for Ehrlich Ascites Adenocarcinoma Proliferation

Document Type : Research and Reference

Authors

1 Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University

2 Medical Biochemistry, Faculty of Medicine, Tanta University

Abstract

Abstract

Cisplatin (cis) is a chemotherapeutic drug used for cancer treatment. The current study intended to investigate the anticancer effect of cis against Ehrlich Ascites Carcinoma (EAC) via suppressing the expression of Akt gene with assessment to its oxidative stress on kidney tissue. The study involved forty female mice which were divided into 4 groups: Group I (Negative control), mice were injected with isotonic saline solution intraperitoneally (i.p). Group II (Cis), mice were injected (i.p) with cis (10 mg/kg) 3times/week. Group III (EAC), mice were injected (i.p) with 0.5x106 EAC cells/mouse/in day "0". Group IV (EAC & cis), mice bearing EAC were treated with cis (10 mg/kg) 3 times /week. At day 14, kidney was isolated and analyzed for oxidative stress and the effect of cis on Akt was evaluated using RT- PCR in EAC cells. The results elucidated the antitumor activity of cis which was proved by decreasing in the number of viable tumor cells, elevating non-viable tumor cells number and down regulating of Akt gene expression. Moreover, treatment of cis was associated with elevating in kidney functions and oxidative stress indices which was observed in significant decrease in catalase (CAT) and glutathione peroxidase (GPx) activities with increasing malondialdehyde (MDA) levels in mice.

Keywords

Main Subjects

Files

Share

How to cite

Statistics